NUCLITHERA AS
Developing targeted alpha and beta emitters for metastatic cancer treatment.
Yleiskatsaus
- 8
- Työntekijät
- 3.2milj NOK
- Liikevaihto
- 2023
- Perustettu
Avainpäättäjät
Øyvind S. Bruland
CMO
Ada Repetto-Llamazares
CSO
Morten Lande
Board Member
Roy Hartvig Larsen
CTO
+1 lisää yhteystietoja Funnelfeedrissä
Kuvaus
NucliThera a.s is a specialized research and development company focused on innovative cancer therapies. The core mission involves creating targeted short-range radionuclides, specifically alpha- and beta-emitters, for treating metastatic cancers. These high-energy nuclides are chemically linked to...